Stoke Therapeutics, Inc.STOKNASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
+7.8%/yr
vs -24.2%/yr prior
5Y CAGR
+7.5%/yr
Consistent
Acceleration
+32.0pp
Accelerating
Percentile
P63
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 54.74% |
| 2024 | 8.39% |
| 2023 | 5.65% |
| 2022 | 43.70% |
| 2021 | 68.24% |
| 2020 | 38.10% |
| 2019 | 178.51% |
| 2018 | 132.66% |
| 2017 | 0.00% |